

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2004

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	4Q '04 vs. 4Q '03					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-	22	N/A	-	4%	22
ARCOXIA	*	77	N/A	-	*	77
CANCIDAS	46%	132	43%	78	52%	54
COZAAR / HYZAAR	11%	764	13%	264	9%	499
CRIXIVAN / STOCRIN	-	62	-38%	9	12%	53
EMEND	*	18	*	16	*	2
FOSAMAX	28%	831	38%	449	18%	382
INVANZ	64%	19	64%	13	64%	6
MAXALT	-3%	91	-6%	61	2%	31
PRIMAXIN	18%	176	*	54	-2%	122
PROPECIA	17%	76	28%	35	9%	41
PROSCAR	16%	194	32%	99	2%	95
SINGULAIR	44%	731	61%	527	13%	204
TIMOPTIC / TIMOPTIC XE	1%	43	-26%	3	3%	40
TRUSOPT / COSOPT	15%	157	20%	67	11%	90
VASOTEC / VASERETIC	-13%	182	N/A	-	-14%	182
VIOXX	N/A	-	N/A	-	N/A	-
ZOCOR	8%	1,311	19%	901	-11%	410
HEPATITIS VACCINES	-12%	47	-14%	38	-11%	8
VIRAL VACCINES	11%	135	11%	123	-8%	13
OTHER VACCINES	13%	104	14%	89	7%	15

* 100% or over

N/A - Not Applicable

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	4Q '04	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	<u>\$ 5,748</u>	<u>2%</u>	<u>-2</u>	<u>2</u>	<u>2</u>
U.S. (\$ MM)	3,373	7%	2	5	N/A
Foreign (\$ MM)	2,375	-4%	-7	-2	5

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
YEAR-TO-DATE
2004

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	DECEMBER YTD `04 vs. DECEMBER YTD `03					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-12%	85	N/A	-	8%	85
ARCOXIA	*	230	N/A	-	*	230
CANCIDAS	56%	430	51%	250	64%	180
COZAAR / HYZAAR	14%	2,824	11%	1,000	15%	1,824
CRIXIVAN / STOCRIN	-12%	256	-68%	29	14%	226
EMEND	76%	47	64%	43	*	4
FOSAMAX	18%	3,160	13%	1,771	25%	1,388
INVANZ	69%	63	55%	44	*	19
MAXALT	-4%	310	-12%	197	13%	112
PRIMAXIN	2%	641	-10%	162	6%	479
PROPECIA	13%	270	16%	129	11%	141
PROSCAR	21%	733	35%	368	9%	365
SINGULAIR	30%	2,622	32%	1,854	26%	768
TIMOPTIC / TIMOPTIC XE	-2%	157	-37%	10	2%	147
TRUSOPT / COSOPT	15%	559	17%	236	14%	323
VASOTEC / VASERETIC	-6%	719	N/A	-	-7%	719
VIOXX ⁽¹⁾	-42%	1,489	-42%	891	-41%	599
ZOCOR	4%	5,197	15%	3,613	-15%	1,583
HEPATITIS VACCINES	-18%	198	-20%	162	-6%	36
VIRAL VACCINES	4%	555	2%	506	22%	49
OTHER VACCINES	1%	284	-1%	227	8%	57

* 100% or over

N/A - Not Applicable

(1) Includes adjustments of \$-492 related to the withdrawal of Vioxx for customer returns of product previously sold recorded in the third quarter of 2004.

	DEC YTD `04 \$	DEC YTD `03 \$	TOTAL % CHG
AZLP REVENUE	1,481	1,912	-23%

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	YTD `04	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	\$ 22,939	2%	-2	1	3
U.S. (\$ MM)	13,472	1%	-3	4	N/A
Foreign (\$ MM)	9,467	3%	-2	-3	8

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2004

OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)

	4Q `04	4Q `03	YTD 2004	YTD 2003
INTEREST INCOME	\$ (90.2)	\$ (72.2)	\$ (300.1)	\$ (308.7)
INTEREST EXPENSE	77.0	80.0	293.7	350.9
EXCHANGE (GAINS)/LOSSES	(28.3)	(3.3)	(18.4)	(28.4)
MINORITY INTERESTS	40.3	37.2	154.2	168.7
AMORTIZATION OF INTANGIBLES	4.4	4.4	18.7	19.2
Other, net	(107.1)	(134.8)	(492.1)	(404.9)
TOTAL	\$ (103.9)	\$ (88.7)	\$ (344.0)	\$ (203.2)

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	4Q `04	4Q `03	YTD 2004	YTD 2003
IVOMEK, HEARTGARD, other avermectins	\$ 117	\$ 124	\$ 452	\$ 477
FRONTLINE	110	91	679	577
Biologicals	133	117	477	423
Other Animal Health	63	59	228	212
Poultry Breeding	36	39	138	145
TOTAL MERIAL SALES	\$ 459	\$ 430	\$ 1,974	\$ 1,834

Sanofi Pasteur-MSD	4Q `04	4Q `03	YTD 2004	YTD 2003
HEPATITIS VACCINES	\$ 20	\$ 18	\$ 81	\$ 74
VIRAL VACCINES	12	11	54	51
Other Vaccines	189	141	672	544
TOTAL SANOFI-MSD SALES	\$ 221	\$ 170	\$ 807	\$ 669

Merck / Schering-Plough Collaboration	4Q `04	4Q `03	YTD 2004	YTD 2003
VYTORIN (Worldwide)	\$ 76	\$ -	\$ 132	\$ -
ZETIA (Worldwide)	328	164	1,053	469
TOTAL	\$ 404	\$ 164	\$ 1,185	\$ 469